Merck Sharp & Dohme (MSD) refers to the Merck organization outside the U.S. and Canada and traces to the historic merger that combined Merck with Sharp & Dohme. It operates as a large pharmaceutical business under the Merck brand architecture.
Recent developments in breast cancer treatment include new clinical trials for advanced disease, findings on CDK4/6 inhibitor sequencing, and discovery of genetic markers explaining drug resistance in HER2-positive breast cancer.
Secondary analysis of KEYNOTE-716 trial finds adjuvant pembrolizumab improves recurrence-free survival in stage IIB/IIC melanoma without increasing new primary melanoma risk, while reducing non-melanoma skin cancers.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07785843 |
A Clinical Study of V503 in Chinese Females Who Have Previously Received a Bivalent Human Papillomavirus (HPV) Vaccine (V503-108) |
NOT_YET_RECRUITING | PHASE3 |
| NCT07785830 |
A Clinical Trial to Evaluate the Effects of MK-4646 on Rosuvastatin in Healthy Participants (MK-4646-007) |
NOT_YET_RECRUITING | PHASE1 |
| NCT07785609 |
A Clinical Trial of MK-2010 With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid Tumors (MK-2010) |
NOT_YET_RECRUITING | PHASE2 |
| NCT07776691 |
A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04) |
NOT_YET_RECRUITING | PHASE3 |
| NCT07776665 |
A Clinical Trial of Enlicitide (MK-0616) Formulations in Healthy Participants (MK-0616-044) |
NOT_YET_RECRUITING | PHASE1 |
| NCT07750158 |
Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease |
NOT_YET_RECRUITING | PHASE3 |
| NCT07748832 |
Pneumococcal Carriage Duration |
RECRUITING | |
| NCT07748351 |
A Clinical Trial of Multiple Formulations of MK-4082 in Healthy Overweight and Obese Participants (MK-4082-007) |
NOT_YET_RECRUITING | PHASE1 |
| NCT07743164 |
A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05) |
NOT_YET_RECRUITING | PHASE3 |
| NCT07743151 |
A Clinical Trial of MK-1406 in Healthy Participants (MK-1406-008) |
NOT_YET_RECRUITING | PHASE1 |
